Belite Bio (NASDAQ: BLTE) has initiated enrollment for the U.S. Phase 3 clinical trial of its lead asset LBS-008 in patients with Stargardt Disease (STGD1), a progressively blinding disease with no approved treatment.
The CNN Money Fear and Greed index remained in the "neutral" zone on Monday amid a sharp decline in the US stocks on Friday.
U.S. Treasury yields rose, as the benchmark 10-year note surged to around 3%, after Germany recorded a record-high surge in monthly producer prices.
Gainers
GigaCloud Technology Inc (NASDAQ: GCT) shares jumped 206% to close at $48.01 on Friday on continued volatility following the company's IPO on Thursday.
On Friday, the SPDR S&P 500 (ACRA: SPY) suffered its first big bearish day since July 26, sliding 1.35% and printing a bearish Marubozu candlestick, which suggests lower prices are likely to come again on Monday.